U084 When to Put Down the Scalpel: Non-Surgical Therapies for Skin Cancer
DESCRIPTION
This session is directed to general dermatologists. We will cover key aspects of non-surgical approaches in non-melanoma skin cancer treatment, including patient selection, counseling, and expected outcomes. We will cover the following non-surgical treatments and provide clinical pearls: topical medications, cryotherapy, photodynamic therapy, intralesional treatments, lasers, and systemic therapies. We also will cover consideration of active surveillance and chemoprevention in select patients. We will describe patient selection for these non-surgical therapies, including consideration of co-morbidities, aversion to surgery, low-risk tumors, high tumor burden, and eruptive KAs.
LEARNING OBJECTIVES
Recognize localized skin cancer cases that would benefit most from non-surgical treatment
Select the optimal non-surgical treatment for localized skin cancer patients
Identify the risks and benefits of active surveillance for localized skin cancer
SCHEDULE
7:30 AM
Localized Non-surgical Treatments for Keratinocyte Carcinoma
Abigail Baird Waldman, MD, FAAD
7:45 AM
Systemic Therapies for Keratinocyte Carcinoma
Nina Ran, MD, MS, FAAD
8:00 AM
Prevention and Active Surveillance for Keratinocyte Carcinoma
Rebecca I. Hartman, MD, MPH, FAAD
8:15 AM
Q&A
DIRECTOR
Rebecca I. Hartman, MD, MPH, FAAD
Brigham and Women's Hospital / Harvard Medical School
SPEAKERS
Nina Ran, MD, MS, FAAD
Abigail Baird Waldman, MD, FAAD
HANDOUTS
DISCLOSURES
Rebecca I. Hartman, MD, MPH, FAAD
Almirall – Consultant (1099 relationship)(Fees); Evereden – Advisory Board(Stock), Consultant(Fees); Lumo Imaging – Advisory Board(No Compensation Received); Med Learning Group – Speaker/Faculty Education(Fees); MJH Life Sciences – Consultant (1099 relationship)(Fees); Moderna Therapeutics – Speaker(Fees); Prime Education – Speaker/Faculty Education(Fees); Veriskin – Investigator(Grants/Research Funding); Vita Imaging – Investigator(Grants/Research Funding); Zura Bio – Data Safety Monitoring Board(Fees);
Nina Ran, MD, MS, FAAD
Chronicle Medical Software – Consultant (1099 relationship)(Fees);
Abigail Baird Waldman, MD, FAAD
No financial relationships exist with ineligible companies.